Pharmacokinetic Properties of Mirabegron, a β3-Adrenoceptor Agonist: Results From Two Phase I, Randomized, Multiple-Dose Studies in Healthy Young and Elderly Men and Women

Clinical Therapeutics

Volumn 34, Issue 10, 2012, Pages 2144-2160

  Krauwinkel, Walter ^a   van Dijk, Jan ^a   Schaddelee, Marloes ^a   Eltink, Charlotte ^a   Meijer, John ^a   Strabach, Grégory ^b   van Marle, Sjoerd ^c   Kerbusch, Virginie ^d   van Gelderen, Marcel ^a  

^a Astellas Pharma Global Development   (Netherlands)

^b SGS Aster   (France)

^c PRA Health Sciences   (Netherlands)

^d PharmAspire Consulting   (Netherlands)

Author keywords

3 adrenoceptor; Elderly; Gender; Mirabegron; Overactive bladder; Pharmacokinetics

Indexed keywords

DRUG METABOLITE; MIRABEGRON;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BLOOD LEVEL; BLOOD PRESSURE MONITORING; BLOOD SAMPLING; BODY POSITION; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG TOLERABILITY; DRUG WITHDRAWAL; ELECTROCARDIOGRAPHY MONITORING; FEMALE; HUMAN; HUMAN EXPERIMENT; KIDNEY CLEARANCE; KIDNEY CONCENTRATING CAPACITY; LABORATORY TEST; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; NORMAL HUMAN; ORTHOSTATIC STRESS; PHASE 1 CLINICAL TRIAL; PHYSICAL EXAMINATION; PULSE RATE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; UNSPECIFIED SIDE EFFECT; URINALYSIS;

ACETANILIDES; ADMINISTRATION, ORAL; ADOLESCENT; ADRENERGIC BETA-3 RECEPTOR AGONISTS; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; AREA UNDER CURVE; CHROMATOGRAPHY, LIQUID; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG MONITORING; FEMALE; HALF-LIFE; HUMANS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; SEX FACTORS; TANDEM MASS SPECTROMETRY; THIAZOLES; TIME FACTORS; YOUNG ADULT;

EID: 84867344252     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2012.09.010     Document Type: Article

References (33)

1. Wein A.J., Rovner E.S. The overactive bladder: an overview for primary care health providers. Int J Fertil Womens Med 1999, 44:56-66.
2. Hu T.W., Wagner T.H., Bentkover J.D., et al. Estimated economic costs of overactive bladder in the United States. Urology 2003, 61:1123-1128.
3. Irwin D.E., Kopp Z.S., Agatep B., et al. Worldwide prevalence estimates of lower urinary tract symptoms, overactive bladder, urinary incontinence and bladder outlet obstruction. BJU Int 2011, 108:1132-1138.
4. Kim S.H., Boye M., Bhattacharyya S.K., et al. Medical visits among adults with symptoms commonly associated with an overactive bladder. BJU Int 2006, 97:551-554.
5. Stewart W.F., Van Rooyen J.B., Cundiff G.W., et al. Prevalence and burden of overactive bladder in the United States. World J Urol 2003, 20:327-336.
6. Athanasopoulos A., Giannitsas K. An overview of the clinical use of antimuscarinics in the treatment of overactive bladder. Adv Urol 2011, 2011:820816.
7. Betanis (mirabegron) tablets [prescribing information] [in Japanese], Accessed July 31, 2012. http://www.info.pmda.go.jp/go/pack/2590014F1021_1_02/.
8. Myrbetriq (mirabegron) [prescribing information], Accessed September 25, 2012. http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/202611s000lbl.pdf.
9. Takasu T., Ukai M., Sato S., et al. Effect of (R)-2-(2-aminothiazol-4-yl)-4'-{2-[(2-hydroxy-2-phenylethyl)amino]ethyl} acetanilide (YM178), a novel selective β3-adrenoceptor agonist, on bladder function. J Pharmacol Exp Ther 2007, 321:642-647.
10. 3-adrenoceptors in urinary bladder. Neurourol Urodyn 2007, 26:752-756.
11. 3-adrenoceptor agonist, in patients with overactive bladder (OAB). Eur Urol Suppl 2010, 9:249.
12. Khullar V., Cambronero J., Stroberg P., et al. The efficacy and tolerability of mirabegron in patients with overactive bladder-results from a European-Australian Phase III trial. Eur Urol Suppl 2011, 10:278-279. Abstract 886.
13. Nitti V., Herschorn S., Auerbach S., et al. The efficacy and safety of mirabegron in patients with overactive bladder syndrome-results from a North-American Phase III trial. Eur Urol Suppl 2010, 10:278. Abstract 885.
14. Ethical Principles for Medical Research Involving Human Subjects. Adopted by the 18th WMA General Assembly and amended by 48th WMA General Assembly, Somerset West, South Africa, October 1996 World Medical Association Declaration of Helsinki, Accessed July 31, 2012. http://www.wma.net/en/30publications/10policies/b3/%20index.html.
15. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. Guideline for Good Clinical Practice E6(R1) Accessed July 31, 2012. http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E6_R1/Step4/E6_R1__Guideline.pdf.
16. van Teijlingen R., Meijer J., Takusagawa S., et al. Development and validation of LC-MS/MS methods for the determination of mirabegron and its metabolites in human plasma and their application to a clinical pharmacokinetic study. J Chromatogr B Analyt Technol Biomed Life Sci 2012, 887-888. 102-111.
17. Rowland M., Tozer T.N. Clinical Pharmacokinetics: Concepts and Application 1995, Lippincott Williams & Wilkins, Baltimore, Md. 3rd ed.
18. Gabrielsson J., Weiner D. Pharmacokinetic and Pharmacodynamic Data Analysis: Concepts and Applications 2007, Swedish Pharmaceutical Press, Stockholm, Sweden. 4th ed.
19. Gough K., Hutchison M., Keene O., et al. Assessment of dose proportionality: report from the statisticians in the pharmaceutical industry/pharmacokinetics UK joint working party. Drug Inf J 1995, 29:1039-1048.
20. Smith B.P., Vandenhende F.R., DeSante K.A., et al. Confidence interval criteria for assessment of dose proportionality. Pharm Res 2000, 17:1278-1283.
21. ICH Topic E7: Studies in support of special populations: geriatrics. CPMP/ICH/379/95 European Medicines Agency European Medicines Agency (EMA), Accessed May 30, 2012. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500002875.pdf.
22. Guidance for Industry. Bioavailability and Bioequivalence Studies for Orally Administered Drug Products-General Considerations US Food and Drug Administration (FDA), Accessed August 16, 2012. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM070124.pdf.
23. Guideline on the investigation of bioequivalence European Medicines Agency (EMA), Accessed August 16, 2012. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2010/01/WC500070039.pdf.
24. ICH Topic M3 (R2): Non-clinical safety studies for the conduct of human clinical trials and marketing authorization for pharmaceuticals European Medicines Agency (EMA), CPMP/ICH/286/95, Accessed May 30, 2012. http://www.emea.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500002720.pdf.
25. Levy R. Time-dependent pharmacokinetics. In "Pharmacokinetics: Theory and Methods,". The International Encyclopedia of Pharmacology and Therapeutics 1982, Pergamon Press, Oxford, UK. M. Rowland, G. Tucker (Eds.).
26. Krauwinkel W.J., van Gelderen E.M., Groen M.J., et al. An open-label, one-sequence crossover study to evaluate the effect of multiple doses of mirabegron on the pharmacokinetics of the CYP2D6 substrate desipramine in healthy subjects. Clin Pharm Ther 2010, 87(Suppl 1):S88.
27. 3-adrenoceptor agonist. Xenobiotica 2012, 42:957-967.
28. 3-adrenoceptor agonist mirabegron in healthy CYP2D6 poor and extensive metabolizers. Clin Pharmacol Ther 2009, 85(Suppl 1):S88.
29. 3-adrenoceptor agonist for treatment of overactive bladder. Int J Clin Pharmacol Ther 2012 Sep 4, [Epub ahead of print].
30. Ushigome F, Takusagawa S, Li Q, et al. Mirabegron, a potent and selective β3-adrenoceptor agonist, is a P-glycoprotein (P-gp) substrate: characterization of its efflux transport in Caco-2 and Human P-gp expressing cells and BCRP and MRP2 expressing vesicles. Drug Metab Rev. In press.
31. 3-adrenoceptor agonist, after oral administration to healthy male volunteers. Drug Metab Dispos 2012, 40:815-824.
32. Dickinson J, Lewand M, Sawamoto T, et al. Effect of renal or hepatic impairment on the pharmacokinetics of mirabegron. Clin Drug Invest. In press.
33. Schwartz J.B. Clinical pharmacology. Cardiovascular Disease in the Elderly 2005, 335-362. Humana Press Inc, Totowa, NJ. G. Gerstenblith (Ed.).